[Featured Stock] Celltrion Starts Up 6.53%... Conditional Approval in Europe

[Asia Economy Reporter Junho Hwang] On the 29th, Celltrion started the trading session at 334,500 KRW, up 6.53%.

Celltrion announced that it received conditional approval from the European Medicines Agency (EMA) for its COVID-19 treatment 'Rekkirona Injection.' As a result, European countries can use Rekkirona based on EMA's usage recommendation before full approval is granted.

Accordingly, Hana Financial Investment estimated that Rekkirona Injection will generate sales of up to 1.2 trillion KRW this year. Minjeong Seon, a researcher at Hana Financial Investment, said, "Celltrion mentioned that the production scale of Rekkirona Injection is up to 3.2 million doses," adding, "They currently have 100,000 doses produced last year, plan to produce 1.3 million doses at Plant 1 this year, and depending on market demand, can produce an additional 1.3 million doses at Plant 2 and about 600,000 doses through overseas contract manufacturing organizations (CMO)." However, she noted, "The maximum production volume estimated by our company is 2 million doses."

This content was produced with the assistance of AI translation services.